PRGO — Perrigo Company plc

Is PRGO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Overbought As of August 19, 2026

Perrigo Company plc (PRGO) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $12.97. The rating moved from Neutral to Overbought on August 13, 2026.

See all overbought Healthcare stocks →

AI analysis

Perrigo Company plc presents a defensive consumer-health profile with stable retail and private-label revenue streams and manufacturing scale that support predictable cash generation. Near-term performance hinges on margin management, contract retention, and input-cost pass-through; execution of efficiency programs and selective product initiatives are the main levers for upside. Market sentiment is currently risk-on, which may favor growth names over defensive healthcare manufacturers in the short run, but Perrigo’s steady cash flow and retailer relationships provide resilience in softer macro scenarios.

Key factors

  • Stable consumer-health and OTC product portfolio with recurring retail and private-label contracts that support predictable cash flows
  • Scale and manufacturing footprint that enable cost advantages for retailers and potential margin resilience vs smaller competitors
  • Ongoing cost-savings and operational efficiency programs that can boost free cash flow if execution remains on track
  • Exposure to retail-channel demand and pharmacy/retail relationships that provide distribution stability
  • Limited direct exposure to current biotech/AI-driven sector rotation; defensive profile may underperform in risk-on rallies but outperforms in downturns
  • Currency and commodity cost sensitivity that can compress margins in an inflationary input-cost environment
  • Potential for selective product innovation, line extensions, or small M&A to provide modest growth upside

Risks

  • Margin pressure from rising input, packaging or logistics costs and inability to fully pass through price increases to retailers
  • Loss or downsizing of large private-label or retail contracts could materially reduce sales and utilization of manufacturing capacity
  • Intense competition from other private-label manufacturers, established branded consumer-health players, and new entrants
  • Macroeconomic slowdown or weaker consumer discretionary spending that reduces nonessential OTC purchases
  • Foreign-exchange volatility given international operations could depress reported revenues and profits
  • Regulatory, quality-control, or recall events at manufacturing sites that could incur costs and reputational damage
  • High leverage or refinancing needs (if present) could limit financial flexibility during adverse conditions
  • Limited benefit from current growth-oriented market themes (AI/biologics) which may lead to short-term relative underperformance

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for PRGO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.